1872. Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College Rhode Island, 2015
Session: Poster Abstract Session: Vaccines: Meningococcal
Saturday, October 10, 2015
Room: Poster Hall
Background: Meningococcal disease is a rare but severe respiratory infection. Asymptomatic nasopharyngeal carriage of N. meningitidis is an important source of transmission, particularly in adolescents and young adults. Serogroup B meningococcal disease caused 4 US university outbreaks since 2013, including one at a Rhode Island college in February 2015. Trumenba, a recently licensed serogroup B meningococcal (MenB) vaccine, was used to control this outbreak. We aimed to estimate meningococcal carriage prevalence among students during this college outbreak and assess Trumenba vaccination impact on carriage.

Methods: Two cross-sectional carriage surveys were conducted in February and April 2015 in conjunction with 1st and 2nddose MenB vaccination campaigns. Questionnaires and oropharyngeal swabs were collected from undergraduates or graduate students living in dorms. Specimens were evaluated using bacterial culture, rtPCR, and molecular typing. Log-linear binomial regression was used to calculate prevalence ratios (PR).

Results: 717 students participated in the 1st survey, and 888 in the 2nd. At baseline, 176 (25%) and 31 (4%) had any meningococcal and serogroup B carriage, respectively. None were carrying the outbreak strain (ST-9069). Additionally, 8 (1%) carried serogroup C, 1 (0%) X, 4 (1%) Y, and 132 (18%) nongroupable N. meningitidis. During the 2ndevaluation, 212 (24%) had any meningococcal carriage, with 36 (4%) carrying serogroup B, 3 (0%) C, 2 (0%) X, 4 (0%) Y, and 167 (19%) nongroupable; molecular typing results are pending. 309 students participated in both evaluations: 229 (74%) remained non-carriers, 18 (6%) acquired carriage, 11 (4%) eradicated carriage, and 51 (17%) remained carriers. Smoking (PR 1.6, 95%CI 1.3-1.9) and partying ≥1 time/week (PR 2.4, 95%CI 1.8-3.1) were associated with any meningococcal carriage.

Conclusion: Baseline carriage was higher than previous US estimates of 1-8%. MenB vaccination had no apparent immediate impact on decreasing overall or serogroup B carriage or preventing carriage acquisition in the 2 months after the 1st dose. Additional strain characterization is ongoing and a final evaluation is planned for September 2015 with the 3rd dose campaign to further monitor Trumenba impact on carriage.

Heidi Soeters, PhD, MPH1,2, Lucy Mcnamara, PhD, MS1,2, Melissa Whaley, MS, MPH2, Xin Wang, PhD2, Nicole Alexander-Scott, MD, MPH3, Kristine Goodwin, BA4, Koren Kanadanian, MS, CEM4, Catherine Kelleher, RN4, Jessica Macneil, MPH2, Stacey W. Martin, MS5, Steven Sears, Ed.D, MBA4, Cindy Vanner, BS, CLS3, Jeni Vuong, BS2, Utpala Bandy, MD, MPH3, Kenneth Sicard, OP, PhD4, Manisha Patel, MD, MS6 and the Rhode Island Meningococcal Carriage Evaluation Team, (1)Epidemic Intelligence Service, CDC, Atlanta, GA, (2)National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA, (3)Rhode Island Department of Health, Providence, RI, (4)Providence College, Providence, RI, (5)Meningitis and Vaccine Preventable Diseases, Centers for Disease Control and Prevention, Atlanta, GA, (6)National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA

Disclosures:

H. Soeters, None

L. Mcnamara, None

M. Whaley, None

X. Wang, None

N. Alexander-Scott, None

K. Goodwin, None

K. Kanadanian, None

C. Kelleher, None

J. Macneil, None

S. W. Martin, None

S. Sears, None

C. Vanner, None

J. Vuong, None

U. Bandy, None

K. Sicard, None

M. Patel, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.